# åˆ¶è¯æ—¥æŠ¥ Pharma Daily

**æ—¥æœŸ**: 2026-01-25
**æ›´æ–°æ—¶é—´**: 2026-01-26 03:56
**æ–°é—»æ•°é‡**: 102

---

## ä»Šæ—¥æ¦‚è§ˆ

## ğŸ“Š AI æ™ºèƒ½åˆ†æ

### ä»Šæ—¥æ¦‚è§ˆ

ä»Šæ—¥åˆ¶è¯è¡Œä¸šåŠ¨æ€èšç„¦äºé‡ç£…è¯ç‰©ä¸´åºŠè¿›å±•ä¸ç›‘ç®¡æ”¿ç­–æ›´æ–°ã€‚èµ›è¯ºè²çš„æ½œåœ¨å…ç–«å­¦é‡ç£…è¯ç‰©åœ¨æ¹¿ç–¹IIIæœŸè¯•éªŒä¸­å–å¾—ç§¯ææ•°æ®ï¼Œä¸ºFDAæäº¤å¥ å®šåŸºç¡€ï¼›FDAå‘å¸ƒå¤šå‘æ€§éª¨é«“ç˜¤è¯ç‰©å¼€å‘æ–°æŒ‡å—ï¼Œæœ‰æœ›åŠ é€Ÿç»†èƒç–—æ³•ç­‰åˆ›æ–°è¯ç‰©å®¡æ‰¹ã€‚åŒæ—¶ï¼Œè¯ºå’Œè¯ºå¾·å£æœWegovyä¸Šå¸‚åˆæœŸè¡¨ç°å¼ºåŠ²ï¼Œæ˜¾ç¤ºå‡ºè‚¥èƒ–ç—‡å£æœè¯ç‰©å¸‚åœºçš„å·¨å¤§æ½œåŠ›ã€‚

### ğŸ”¥ é‡ç‚¹æ–°é—»

**2. Sanofi's Phase 3 eczema data cloud hopes for potential immunology blockbuster** â­â­â­â­â­
   - ç±»åˆ«: ä¸´åºŠè¯•éªŒ
   - èµ›è¯ºè²æ½œåœ¨å…ç–«å­¦é‡ç£…è¯ç‰©å–å¾—å…³é”®IIIæœŸç§¯ææ•°æ®ï¼Œå°†æäº¤FDAå®¡æ‰¹ï¼Œå¯¹å…ç–«ç–¾ç—…æ²»ç–—é¢†åŸŸæœ‰é‡å¤§å½±å“ã€‚

**5. J&J praises new FDA guidance to speed development of multiple myeloma drugs** â­â­â­â­â­
   - ç±»åˆ«: æ”¿ç­–æ³•è§„
   - FDAå‘å¸ƒå¤šå‘æ€§éª¨é«“ç˜¤è¯ç‰©å¼€å‘æ–°æŒ‡å—ï¼Œå…è®¸ä½¿ç”¨å¾®å°æ®‹ç•™ç—…ä½œä¸ºä¸»è¦ç»ˆç‚¹ï¼Œå°†æ˜¾è‘—åŠ é€Ÿç»†èƒç–—æ³•ç­‰åˆ›æ–°è¯ç‰©å®¡æ‰¹è¿›ç¨‹ã€‚

**9. Novo's Wegovy pill launch wows with strong early uptake: analysts** â­â­â­â­
   - ç±»åˆ«: å¸‚åœºåˆ†æ
   - è¯ºå’Œè¯ºå¾·å£æœWegovyä¸Šå¸‚ç¬¬äºŒå‘¨å¤„æ–¹é‡è¾¾1.84ä¸‡ï¼Œè¿œè¶…é¢„æœŸï¼Œæ˜¾ç¤ºå£æœGLP-1è¯ç‰©åœ¨è‚¥èƒ–ç—‡å¸‚åœºçš„å·¨å¤§å•†ä¸šæ½œåŠ›ã€‚

**12. Led by Darzalex surge, J&J expects revenue to reach $100B in 2026** â­â­â­â­
   - ç±»åˆ«: å¸‚åœºåˆ†æ
   - å¼ºç”Ÿé¢„è®¡2026å¹´è¥æ”¶å°†è¾¾1000-1010äº¿ç¾å…ƒï¼Œä¸»è¦å—Darzalexç­‰æ ¸å¿ƒè¯ç‰©é©±åŠ¨ï¼Œåæ˜ å…¶å¼ºåŠ²å¢é•¿å‰æ™¯ã€‚

**24. STAT+: GSK to buy RAPT Therapeutics, maker of food allergy treatment, in $2.2B deal** â­â­â­â­
   - ç±»åˆ«: å•†ä¸šåŠ¨æ€
   - GSKä»¥22äº¿ç¾å…ƒæ”¶è´­RAPT Therapeuticsï¼Œè·å¾—å®éªŒæ€§é£Ÿç‰©è¿‡æ•æ²»ç–—è¯ç‰©ï¼ŒåŠ å¼ºå…¶å…ç–«å­¦ç®¡çº¿å¸ƒå±€ã€‚

### ğŸ“ åˆ†ç±»æ‘˜è¦

**æ–°è¯ç ”å‘** (Drug R&D): F2Gè®¡åˆ’6æœˆæ”¶é›†IIIæœŸæ•°æ®åé‡æ–°æäº¤æŠ—çœŸèŒè¯olorofimï¼›IntraBioçš„Aqneursaåœ¨ç½•è§ç¥ç»é€€è¡Œæ€§ç–¾ç—…ä¸­å–å¾—IIIæœŸæˆåŠŸï¼›Corvusæ¹¿ç–¹å£æœè¯æ—©æœŸæ•°æ®ç§¯æï¼Œæ˜¾ç¤ºITKæŠ‘åˆ¶å‰‚æ½œåŠ›ï¼›æŠ•èµ„è€…å‘Corxelæ³¨èµ„2.87äº¿ç¾å…ƒå¼€å‘å·®å¼‚åŒ–å£æœè‚¥èƒ–ç—‡è¯ç‰©ã€‚
**ä¸´åºŠè¯•éªŒ** (Clinical Trials): èµ›è¯ºè²æ¹¿ç–¹è¯ç‰©åœ¨ä¸¤é¡¹IIIæœŸç ”ç©¶ä¸­æˆåŠŸï¼›Bausch Healthçš„Xifaxanæ–°é…æ–¹IIIæœŸå¤±è´¥ï¼›CEPIèµ„åŠ©3000ä¸‡ç¾å…ƒä¸é»˜å…‹ç­‰åˆä½œå¼€å‘æ”¹è¿›å‹åŸƒåšæ‹‰ç–«è‹—ï¼›Corvusæ¹¿ç–¹å£æœè¯æ—©æœŸæ•°æ®ç§¯æã€‚

### ğŸ”® æ˜æ—¥å…³æ³¨

å…³æ³¨èµ›è¯ºè²æ¹¿ç–¹è¯ç‰©FDAæäº¤æ—¶é—´è¡¨åŠåç»­ç›‘ç®¡è¿›å±•ï¼›è·Ÿè¸ªè¯ºå’Œè¯ºå¾·å£æœWegovyçš„å¸‚åœºæ¸—é€ç‡å˜åŒ–åŠç«äº‰æ ¼å±€ï¼›ç•™æ„FDAå¤šå‘æ€§éª¨é«“ç˜¤æ–°æŒ‡å—å¯¹ç›¸å…³è¯ç‰©å¼€å‘é¡¹ç›®çš„å…·ä½“å½±å“ï¼›è§‚å¯ŸGSKæ”¶è´­RAPT Therapeuticsåç®¡çº¿æ•´åˆæƒ…å†µã€‚


---

## æ•°æ®ç»Ÿè®¡

| ç±»åˆ« | æ•°é‡ |
|------|------|
| æ–°è¯ç ”å‘ (Drug R&D) | 34 |
| ç»¼åˆ (ç»¼åˆ) | 40 |
| ç›‘ç®¡å®¡æ‰¹ (Regulatory) | 20 |
| å•†ä¸šåŠ¨æ€ (Business/M&A) | 8 |

---

## æ–°è¯ç ”å‘ | Drug R&D

### ğŸ‡ºğŸ‡¸ F2G CEO outlines biotech's FDA resubmission plans, funding and expansion

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-23 16:38
- **é‡è¦æ€§**: â­â­â­â­â­

> F2G plans to resubmit its antifungal to the FDA after collecting Phase 3 data this coming June, CEO Francesco Maria Lavino told Endpoints News. The biotech's oral candidate, called olorofim, was

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/f2g-ceo-outlines-biotechs-fda-resubmission-plans-funding-and-expansion/)

---

### ğŸ‡ºğŸ‡¸ Sanofi's Phase 3 eczema data cloud hopes for potential immunology blockbuster

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-23 15:39
- **é‡è¦æ€§**: â­â­â­â­â­

> The centerpiece of Sanofiâ€™s immunology efforts succeeded in two more Phase 3 eczema studies in the US, the company announced Friday, setting up a possible FDA submission before the end of ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/sanofis-phase-3-eczema-data-cloud-hopes-for-potential-immunology-blockbuster/)

---

### ğŸ‡ºğŸ‡¸ Another biopharma tried buying Amicus before BioMarin's $4.8B deal

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-22 15:16
- **é‡è¦æ€§**: â­â­â­â­

> The road to Amicus Therapeuticsâ€™ $4.8 billion exit to BioMarin last month included a previously undisclosed acquisition offer from another biopharma, quiet dinners between CEOs, and a months-long push to settle a ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/another-biopharma-tried-buying-amicus-before-biomarins-4-8b-deal/)

---

### ğŸ‡ºğŸ‡¸ J&J praises new FDA guidance to speed development of multiple myeloma drugs

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-21 18:35
- **é‡è¦æ€§**: â­â­â­â­

> Johnson &amp; Johnson, which has several drugs approved for multiple myeloma, praised the FDA's just-released draft guidance on how the agency will allow the use of minimal residual disease as a primary endpoint for accelerated ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/jj-praises-new-fda-guidance-to-speed-development-of-multiple-myeloma-drugs/)

---

### ğŸ‡ºğŸ‡¸ Sanofi to seek approval of touted eczema drug despite mixed results

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-23 16:57
- **é‡è¦æ€§**: â­â­

> Fresh data from multiple studies suggest the drug, which Sanofi has billed as a future blockbuster, could be cleared in the U.S. but has murky sales prospects.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/sanofi-amlitelimab-eczema-atopic-dermatitis-drug-results/810353/)

---

### ğŸ‡ºğŸ‡¸ Investors load Corxel with $287M for a â€˜differentiatedâ€™ obesity pill

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-22 19:00
- **é‡è¦æ€§**: â­â­

> The funding will support a GLP-1 pill Corxel licensed from China-based Vincentage in 2024 and that the company believes to be as effective in spurring weight loss as injectable therapies.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/corxel-oral-glp1-vincentage-series-d-china-deal/810242/)

---

### ğŸ‡ºğŸ‡¸ FDA lays out new path to speed development of multiple myeloma drugs

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-22 16:36
- **é‡è¦æ€§**: â­â­

> In certain cases, regulators will now be open to clearing therapies based on their ability to eliminate tumor cells, a change that could accelerate cell therapies and other new medicines.&nbsp;

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/fda-multiple-myeloma-accelerated-approval-pathway/810219/)

---

### ğŸ‡ºğŸ‡¸ Corvus shares nearly triple on positive data for eczema pill

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-21 16:39
- **é‡è¦æ€§**: â­â­

> While early, the results indicate drugs known as ITK inhibitors have the potential to match or surpass the efficacy observed with the injectable biologic Dupixent.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/corvus-soquelitinib-phase-1-data-eczema-pill/810080/)

---

### ğŸ‡ºğŸ‡¸ First-movers respond to herding; BioMarin vets start new biotech; GSK buys RAPT Therapeutics; and more

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-24 11:00
- **é‡è¦æ€§**: â­â­

> Welcome back to another edition of Endpoints Weekly. Though we may have had a short week with Martin Luther King Jr. Day, the news kept on coming. Letâ€™s dive in. We had a little bit ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/first-movers-respond-to-herding-biomarin-vets-start-new-biotech-gsk-buys-rapt-therapeutics-and-more/)

---

### ğŸ‡ºğŸ‡¸ ACIP members depict diverging goals after schedule change

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-23 18:24
- **é‡è¦æ€§**: â­â­

> Fresh off health officialsâ€™ sweeping remake of the US childhood vaccine schedule, two members of a key CDC panel are depicting different versions of the committeeâ€™s work moving forward. Comments made this week by Robert ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/acip-members-depict-diverging-goals-after-schedule-change/)

---

### ğŸ‡ºğŸ‡¸ Former FDA deputies land at Lilly, AbbVie; Italy's Angelini has a new CEO

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-23 12:00
- **é‡è¦æ€§**: â­â­

> â†’ Eli Lilly is one of many large pharmas that have hired displaced or disgruntled FDA officials in the past year, and Karin Bok is its latest pickup. Bok resigned in November as deputy director ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/former-fda-deputies-land-at-lilly-abbvie-italys-angelini-has-a-new-ceo/)

---

### ğŸ‡ºğŸ‡¸ Roche boosts NC factory investment to $2B; Rentschler CEO steps down

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-22 15:39
- **é‡è¦æ€§**: â­â­

> Rocheâ€™s Genentech is topping up its investment into its Holly Springs, NC, factory to reach nearly $2 billion. The extra investment will also add an additional 100 jobs at the site ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/roche-boosts-nc-factory-investment-to-2b-rentschler-ceo-steps-down/)

---

### ğŸ‡ºğŸ‡¸ Novo climbs higher on â€˜strongâ€™ Wegovy pill launch; Terns tweaks leukemia drug deal

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-23 15:27
- **é‡è¦æ€§**: â­

> Novo shares have surged more than 20% amid oral Wegovy&rsquo;s fast start.&nbsp;Elsewhere, Terns opened up room for a potential partnership and Corcept solidified its case for an ovarian cancer drug.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/wegovy-pill-prescriptions-terns-deal-corcept-data-biomerieux/810253/)

---

### ğŸ‡ºğŸ‡¸ Bristol Myers buys into Januxâ€™s â€˜maskedâ€™ T cell engagers

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-22 17:00
- **é‡è¦æ€§**: â­

> Worth up to $850 million, the partnership provides &ldquo;further validation&rdquo; for Janux at a time of heightened investor scrutiny regarding the potential of its top drug, one analyst wrote.&nbsp;

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/janux-bristol-myers-partnership-t-cell-engagers-cancer/810227/)

---

### ğŸ‡ºğŸ‡¸ EU kicks off one-year pilot to expedite multinational trials

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-23 19:24
- **é‡è¦æ€§**: â­

> The European Union unveiled details of a pilot project that aims to accelerate the timeline for starting new multinational clinical trials. The voluntary pilot, called FASTâ€‘EU, will feature a maximum 10â€‘week (70â€‘day) timeline from drugmaker ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/eu-kicks-off-one-year-pilot-to-expedite-multinational-trials/)

---

### ğŸ‡ºğŸ‡¸ Congress eyes tackling healthcare consolidation

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-23 14:42

> &ldquo;I think there&rsquo;s common ground here,&rdquo; one Republican congressman said Wednesday during a House Budget Committee hearing. Squaring up against healthcare monopolies would be a major pivot for the GOP.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/house-budget-committee-healthcare-affordability-consolidation/810333/)

---

### ğŸ‡ºğŸ‡¸ BioMarin vets form Mendra to â€˜modernizeâ€™ rare disease drug development

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-22 16:02

> Backed with $82 million and led by two of BioMarin&rsquo;s former executives, Mendra&nbsp;plans to acquire rare disease assets and use AI to help accelerate their development.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/mendra-rare-disease-biotech-startup-ai-biomarin-financing/810204/)

---

### ğŸ‡ºğŸ‡¸ J&J eyes $100B in sales amid gains for cancer, immune drugs

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-21 16:04

> Amid patent expirations, litigation and tariff costs, J&amp;J says it expects more growth ahead, fueled in part by its blood cancer medicines and a closely watched psoriasis pill.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/johnson-johnson-2025-earnings-sales-cancer-immune-drugs/810097/)

---

### ğŸ‡ºğŸ‡¸ Moderna cancer vaccine holds up; IO Biotech considers a sale

- **æ¥æº**: BioPharma Dive
- **æ—¶é—´**: 2026-01-21 15:38

> Long-term data suggest Moderna&rsquo;s personalized melanoma shot provides &ldquo;durable tumor control,&rdquo; one analyst said. Elsewhere, Insilico Medicine partnered with a startup on a popular drug target.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.biopharmadive.com/news/moderna-melanoma-io-biotech-nlrp3-think-pfizer-novavax/809958/)

---

### ğŸ‡ºğŸ‡¸ Novo's Wegovy pill off to a solid start after just two weeks on market

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-23 20:23

> Novo Nordiskâ€™s weight loss pill is off to an impressive start after less than three weeks on the market. Prescriptions are quickly ramping up, increasing by roughly 500% in the pillâ€™s second week, analysts said ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/novos-wegovy-pill-off-to-a-solid-start-after-just-two-weeks-on-market/)

---

### ğŸ‡ºğŸ‡¸ Lilly was the only pharma bidder for Ventyx

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-23 12:20

> Eli Lilly had very little competition in its eventual deal for Ventyx Biosciences, one of the leading drug developers in the hot NLRP3 arena. The Indianapolis drug giant scooped up the San Diego biotech for ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/lilly-was-the-only-pharma-bidder-for-ventyx/)

---

### ğŸ‡ºğŸ‡¸ Insurance CEOs defend their businesses at House hearing

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-23 12:10

> The CEOs of the biggest US health insurers defended their business practices before a House hearing Thursday on the soaring cost of health coverage. Republican and Democratic lawmakers slammed insurers for hiking premiums, delaying care ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/insurance-ceos-defend-their-businesses-at-house-hearing/)

---

### ğŸ‡ºğŸ‡¸ High court picked Hikmaâ€™s â€˜skinny labelâ€™ fight after letting the issue â€˜percolateâ€™

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-22 19:53

> Generic and brand-name drugmakers have been divided for decades over the use of â€œskinny labelsâ€ to bring lower-cost drugs to market. Now, the Supreme Court is taking up the issue. Itâ€™s wading into a case ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/high-court-picked-hikmas-skinny-label-fight-after-letting-the-issue-percolate/)

---

### ğŸ‡ºğŸ‡¸ Drugmakers spent less on Washington lobbying in 2025's final quarter

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-22 18:35

> The top five biopharma company spenders on congressional lobbying spent slightly less in Washington in the final quarter of 2025 than they did in the previous quarter, the latest Senate disclosures show. Pfizer and Johnson ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/drugmakers-spent-less-on-washington-lobbying-in-2025s-final-quarter/)

---

### ğŸ‡ºğŸ‡¸ Corcept's drug extends patients' lives in key ovarian cancer study

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-22 16:08

> Corcept Therapeutics said its experimental drug cut the risk of death by 35% for patients with a challenging form of ovarian cancer when added on top of chemotherapy, notching an important win after the California ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/corcepts-drug-extends-patients-lives-in-key-ovarian-cancer-study/)

---

### ğŸ‡ºğŸ‡¸ China-founded pharma Corxel raises up to $287M for oral GLP-1

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-22 16:00

> Since its 2019 founding, Corxel Pharmaceuticals has evolved from focusing on the China market to eyeing the world. The biopharma, founded in Shanghai but now headquartered in New Jersey, has raised as much as ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/china-founded-pharma-corxel-raises-up-to-287m-for-oral-glp-1/)

---

### ğŸ‡ºğŸ‡¸ Health insurance CEOs head to DC

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-22 15:39

> We donâ€™t know if President Donald Trump made good on plans to meet with major health insurers yet, but their CEOs are slated to testify today before two congressional committees ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/health-insurance-ceos-head-to-dc/)

---

### ğŸ‡ºğŸ‡¸ Bristol Myers signs deal with Janux on T cell engager for $50M upfront

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-22 15:15

> Janux Therapeutics has found a new partner. The San Diego-based biotech is teaming up with Bristol Myers Squibb on a solid tumor program, but the target is not yet disclosed. Bristol ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/bristol-myers-signs-deal-with-janux-on-t-cell-engager-for-50m-upfront/)

---

### ğŸ‡ºğŸ‡¸ Erasca, Corvus, BioAge target $500M+ offerings

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-22 14:43

> Plus, news about Ipsen, Galderma, PAQ Therapeutics and Resolve M Therapeutics: ğŸ’° Public offering roundup: Erasca is selling more than 22 million shares at $10 apiece, targeting $225 million in ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/erasca-corvus-bioage-target-500m-offerings/)

---

### ğŸ‡ºğŸ‡¸ #JPM26: Hua Medicine plots diabetes drug expansion in China and beyond

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-22 12:00

> Shanghai-based Hua Medicine wants to capture a greater share of the global diabetes market with a different approach from popular GLP-1 medicines. Many newer diabetes drugs mimic gut hormones to regulate glucose. Hua's drug for ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/hua-medicine-plots-diabetes-drug-expansion-in-china-and-beyond/)

---

### ğŸ‡ºğŸ‡¸ BioMarin vets spearhead new biotech with $82M for rare disease drugs

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-22 12:00

> A fresh biotech has raised $82 million to scour the landscape of rare disease medicines that need a new home for further development and apply lessons from executives' experiences at BioMarin. The Bay Area startup ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/biomarin-vets-spearhead-new-biotech-with-82m-for-rare-disease-drugs/)

---

### ğŸ‡ºğŸ‡¸ The status of EU drug price talks depends on who you ask

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-21 20:33

> One of the main questions for drugmakers entering 2026, and one they hope tilts in their favor, is whether the US will successfully pressure Europe to raise the price it pays for drugs. Three weeks ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/the-status-of-eu-drug-price-talks-depends-on-who-you-ask/)

---

### ğŸ‡ºğŸ‡¸ Johnson & Johnson brushes off MFN impact, sees strong growth for 2026

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-21 16:43

> As the calendar turns from JPM to quarterly reports, earnings bellwether Johnson &amp; Johnson makes its return for 2026. The focus this time? How biopharma will react to a slate of most favored nation deals ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/johnson-johnson-brushes-off-mfn-impact-sees-strong-growth-for-2026/)

---

### ğŸ‡ºğŸ‡¸ Tanabe pill delays blood disorder; enGene adds up to $100M from loans

- **æ¥æº**: Endpoints News
- **æ—¶é—´**: 2026-01-21 16:25

> Plus, news about IO, ErVimmune, Affibody, Clasp Therapeutics and Infinitopes: ğŸ’Š Tanabe Pharmaâ€™s pill succeeds in rare blood conditions: The biotechâ€™s oral melanocortin-1 receptor delayed the onset of symptoms in a ...

ğŸ”— [é˜…è¯»åŸæ–‡](https://endpoints.news/tanabe-pill-delays-blood-disorder-engene-adds-up-to-100m-from-loans/)

---

## ç»¼åˆ | ç»¼åˆ

### ğŸ‡ºğŸ‡¸ Samsung Bio sticks landing on 2025 as it becomes first Korean biopharma to hit 2T won profit threshold

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-22 07:36
- **é‡è¦æ€§**: â­â­â­â­

> CDMO Samsung Biologics grew sales more than 30% last year to around 4.6 trillion Korean won ($3.1 billion) and lifted its 2025 operating profit to roughly 2.07 trillion won ($1.4 billion). Samsung Bio is now the first Korean biotech or pharmaceutical company to surpass the 2 trillion won annual profit threshold, local news outlets reported this week.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/samsung-bio-sticks-landing-2025-it-becomes-first-korean-biopharma-hit-2-trillion-won-profit)

---

### ğŸ‡ºğŸ‡¸ Bausch Health's $2B pursuit of Xifaxan successor hits wall with phase 3 failure

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-23 10:08
- **é‡è¦æ€§**: â­â­â­

> A potential inflection point that Bausch Health hoped could diversify its portfolio has vanished with a pair of phase 3 failures for a new formulation of the companyâ€™s bread-and-butter Xifaxanâ€”a setback that leaves a $2 billion hole in its growth plan.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/bausch-healths-2b-pursuit-xifaxan-successor-hits-wall-phase-3-failure)

---

### ğŸ‡ºğŸ‡¸ CEPI bankrolls $30M Ebola vaccine collaboration with Merck, SK Bioscience and others

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-22 10:54
- **é‡è¦æ€§**: â­â­â­

> The project, which involves Merck, SK Bioscience, Hilleman Laboratories and CDMO IDT Biologika, aims to make Merck's current Ebola vaccine easier to manufacture and store, prompting broader global accessibility.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/cepi-bankrolls-30m-ebola-vaccine-collaboration-merck-sk-biosciences-and-others)

---

### ğŸ‡ºğŸ‡¸ IntraBio's Aqneursa, on a roll with EU approval, races toward another rare disease indication with phase 3 win

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-21 11:04
- **é‡è¦æ€§**: â­â­â­

> The company announced a phase 3 win in the rare neurodegenerative disease Ataxia-telangiectasia on the same day it snagged a key European approval in the drug's original indication of Niemann-Pick disease type C.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/intrabios-aqneursa-roll-eu-approval-races-toward-another-rare-disease-indication-phase-3-win)

---

### ğŸ‡ºğŸ‡¸ Novo's Wegovy pill launch wows with strong early uptake: analysts

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-23 09:42
- **é‡è¦æ€§**: â­â­

> In the second week of oral Wegovyâ€™s launch, which ended Jan. 16, the obesity pill logged roughly 18,400 total prescriptions, according to IMS data cited by Jefferies. That performance is a fair bit better than that of either injectable Wegovy or Eli Lilly's Zepbound during the first two weeks of their respective rollouts, the analyst team noted.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/novos-impressive-wegovy-pill-launch-headline-and-itself-evercore-says)

---

### ğŸ‡ºğŸ‡¸ Fierce Pharma Asiaâ€”Astellas CEO's BD plan; Takeda's US layoffs; Chugai's chase for name recognition

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-22 15:31
- **é‡è¦æ€§**: â­â­

> Astellas CEO said he doesn't want to make acquisitions simply to fill a revenue gap. Takeda is preparing for Trintellix's U.S. patent expiry with a round of layoffs. Chugai's CEO is seeking name recognition as the Roche unit looks for more external partners. And more.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/astellas-ceo-bd-plan-takeda-us-layoffs-chugai-chase-name-recognition)

---

### ğŸ‡ºğŸ‡¸ Biosimilar execs optimistic about future for US biosims as Sandoz locks in on â€˜golden decadeâ€™ to come

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-21 17:07
- **é‡è¦æ€§**: â­â­

> Executives from top U.S. biosimilar makers are optimistic about the future of U.S. biosimilar adoption as recent FDA guidance seeks to streamline biosimilar development and potentially dissipate the upcoming â€œbiosimilar void.â€

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/biosimilar-execs-remain-optimistic-state-us-biosimilars-while-sandoz-locks-golden-decade)

---

### ğŸ‡ºğŸ‡¸ Led by Darzalex surge, J&amp;J expects revenue to reach $100B in 2026

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-21 11:20
- **é‡è¦æ€§**: â­â­

> Led by cancer standout Darzalex, Johnson &amp; Johnson projects that its 2026 revenue will reach between $100 billion and $101 billion. With J&amp;J also forecasting double-digit revenue increases by the end of the decade, the drugmaker may be on its way to kicking off a $100-billion-plus annual revenue streak.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/led-darzalex-surge-jj-expects-revenue-reach-100b-2026)

---

### ğŸ‡ºğŸ‡¸ STAT+: Pharmalittle: Weâ€™re reading about drug shortages, llama antibodies for developing meds, and more

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-23 14:27
- **é‡è¦æ€§**: â­â­

> The number of ongoing prescription drug shortages rose slightly in the last quarter of 2025, but remained significantly lower than the all-time high reached in 2024

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/01/23/moderna-vaccines-cigna-shortages-cancer-obesity-weight/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: The number of new drug shortages in U.S. hits lowest level in 20 years, but myriad problems remain

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-22 17:40
- **é‡è¦æ€§**: â­â­

> The number of ongoing prescription drug shortages rose slightly in the last quarter of 2025, but remained significantly lower than the all-time high reached in the beginning of 2024.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/01/22/medicines-pharma-biotech-shortages-hospitals-injectables/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Pharmalittle: Weâ€™re reading about Canada speeding drug reviews, Novo Nordisk ads, and more

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-21 14:14
- **é‡è¦æ€§**: â­â­

> Health Canada is planning to speed up reviews of some drugs by piggybacking on the decisions of foreign regulators, including possibly the U.S. FDA

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/01/21/canada-vaccines-novo-eczema-diabetes/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: GSK to buy RAPT Therapeutics, maker of food allergy treatment, in $2.2B deal

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-20 08:01
- **é‡è¦æ€§**: â­â­

> GSK is buying RAPT Therapeutics in a deal worth $2.2 billion, picking up an experimental medicine for food allergies.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/01/20/gsk-rapt-therapeutics-acquisition-food-allergy-prophylaxis-ozureprubart/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ Anti-vaccine sentiment pushes Moderna away from new late-stage infectious disease trials

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-23 11:55
- **é‡è¦æ€§**: â­

> As the Trump administration erodes U.S. infrastructure supporting infectious disease vaccines, mRNA heavyweight Moderna plans to pull away from late-stage clinical trial investments in the area.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/biotech/anti-vaccine-sentiment-pushes-moderna-away-new-late-stage-infectious-disease-trials)

---

### ğŸ‡ºğŸ‡¸ Lilly battles weight stigma in short film centering obesity conversation on health, not appearance

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-23 11:52

> GLP-1 giant Eli Lilly has once again taken to the medium of short film to get an important message about obesity across.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/marketing/lilly-battles-weight-stigma-short-film-centering-obesity-conversation-health-not)

---

### ğŸ‡ºğŸ‡¸ RFK Jr.'s new ACIP chair stresses 'individual autonomy,' questions polio shot guidance on podcast

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-23 10:19

> The new chairman of the CDC's Advisory Committee on Immunization Practices, Kirk Milhoan, M.D., Ph.D., recently took to the podcast â€œWhy Should I Trust You?â€ to answer exactly that.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/new-acip-chair-talks-established-science-polio-vaccine-uncertainty-and-individual-autonomy)

---

### ğŸ‡ºğŸ‡¸ ST Pharm inks $56M deal to produce API for a US biotech

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-23 10:15

> ST Pharm has struck a $56 million deal with an undisclosed U.S.-based biotech to produce active pharmaceutical ingredients (APIs) for a new oligonucleotide treatment. The Korean CDMO revealed the contract Friday in a regulatory filing.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/manufacturing/st-pharm-inks-56m-deal-produce-apis-us-biotech)

---

### ğŸ‡ºğŸ‡¸ Ocular drafts Eylea launch architect to lead attack on Regeneron's blockbuster

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-23 07:18

> Plotting a challenge to Regeneronâ€™s blockbuster Eylea, Ocular Therapeutix has hired â€œa key architectâ€ of its rivalâ€™s launch to head its commercial team.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/marketing/ocular-drafts-eylea-launch-architect-lead-attack-regenerons-blockbuster)

---

### ğŸ‡ºğŸ‡¸ JPM26: Sunshine, AI and the deals that weren't

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-22 10:09

> Fierceâ€™s Zoey Becker, Angus Liu and Gabrielle Masson unpack the key topics and trends that stood out at this yearâ€™s J.P. Morgan Healthcare Conference.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/recapping-2026-jp-morgan-healthcare-conference)

---

### ğŸ‡ºğŸ‡¸ Global pharma manufacturing output surged in '25 in 'front-loading' response to US tariff threats: report

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-22 15:19

> While the threat of U.S. import tariffs prompted a surge in drug production last year, that output is slated to slow across multiple geographies in 2026, according to a new report from financial services firm Atradius.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/manufacturing/pharma-manufacturing-output-surged-25-countries-braced-us-tariffs-atradius)

---

### ğŸ‡ºğŸ‡¸ Invivyd teams up with Olympic skier Lindsey Vonn for antibody education

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-22 10:54

> As Lindsey Vonnâ€™s comeback run heads toward a peak with Team USA at the upcoming 2026 Winter Olympics, Invivyd is adding the professional skier to its team, too.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/marketing/invivyd-teams-olympic-skier-lindsey-vonn-antibody-education)

---

### ğŸ‡ºğŸ‡¸ Lundbeck â€˜not willing to compromiseâ€™ on M&amp;A strategy after missed Avadel attempt: exec

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-22 10:23

> Despite falling short in its recent bid to snatch Avadel from Alkermes, Lundbeck is signaling to investors that itâ€™s not desperate for deals and will not lower its standards for future M&amp;A transactions.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/lundbeck-not-willing-compromise-ma-strategy-after-missed-avadel-attempt)

---

### ğŸ‡ºğŸ‡¸ Trump's Davos drug pricing claims decried as 'fake news' by French presidency

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-22 09:57

> After U.S. President Donald Trump took the stage at the World Economic Forum this week to tout the supposed success of his tariff-tinged trade negotiations, the French presidency has pushed back against a drug pricing claim that itâ€™s branding â€œfake news.â€

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/trumps-davos-drug-pricing-claims-decried-fake-news-french-presidency)

---

### ğŸ‡ºğŸ‡¸ In J&amp;J talc litigation, N.J. court-appointed official recommends allowing expert testimony

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-21 15:13

> In Johnson &amp; Johnson's long-running talc litigation, a court-appointed special master has recommended that plaintiffs should be able to present testimony from expert witnesses who can speak to scientific evidence backing their claims. The decision could negatively impact the company's defense of lawsuits from those who claim Johnsonâ€™s Baby Powder caused their cancer.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/jj-talc-litigation-nj-court-recommends-allow-expert-testimony)

---

### ğŸ‡ºğŸ‡¸ UPDATE: In quick reversal, Trump calls off tariff threat related to Greenland pursuit

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-20 09:55

> Only a few days after threatening to impose new tariffs on a group of European countries related to his pursuit of Greenland, the president has called off the threat.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/trumps-new-tariff-threats-around-greenland-threaten-upend-eu-trade-deal)

---

### ğŸ‡ºğŸ‡¸ Pfizer CEO lays blame for US vaccine woes on RFK Jr.'s 'anti-science' stance: WSJ

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-21 09:46

> While much of the biopharma industry has spent the past 12 months treading lightly around the Trump administration and the tumult it has wrought on U.S. medical research and regulation, Pfizerâ€™s CEO cut to the chase this week in a blatant rebuke of HHS Secretary Robert F. Kennedy Jr., according to The Wall Street Journal.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/pfizer-ceo-lays-blame-us-vaccine-woes-anti-science-rfk-jr-wsj)

---

### ğŸ‡ºğŸ‡¸ Rising Stars: Regeneronâ€™s Catie Matthews on updating marketing strategy to meet the AI boom

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-20 12:30

> In a Q&amp;A for Fierce Pharma Marketingâ€™s â€œRising Starsâ€ series, Catie Matthews suggested that marketers should embrace artificial intelligence in their own lives.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/marketing/rising-stars-regenerons-catie-matthews-updating-marketing-strategy-amid-ai-boom)

---

### ğŸ‡ºğŸ‡¸ GSK licenses Alteogen enzyme in bid to develop subQ Jemperli

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-20 14:08

> GSK, through its oncology subsidiary Tesaro, is handing over $20 million upfront to Alteogen for global rights to the Korean biotechâ€™s novel hyaluronidase ALT-B4. Tesaro plans to use ALT-B4 to develop and potentially market a subcutaneous form of the ascendant cancer med Jemperli.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/gsk-offers-alteogen-285m-subq-jemperli-licensing-pact)

---

### ğŸ‡ºğŸ‡¸ Takeda's neuroscience field force hit with layoffs as key patent loss looms for Trintellix

- **æ¥æº**: FiercePharma
- **æ—¶é—´**: 2026-01-20 13:14

> Takeda is executing another round of layoffs, cutting 243 roles in the U.S. The company is preparing for an upcoming patent loss on depression drug Trintellix.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.fiercepharma.com/pharma/takeda-cuts-243-us-workers-generic-competition-looms-trintellix)

---

### ğŸ‡ºğŸ‡¸ STAT+: Up and down the ladder: The latest comings and goings

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-23 17:19

> From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/01/23/pharma-biotech-jobs-teva-novartis-novo-lilly/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Insurers blame drugmakers, hospitals for high prices

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-23 15:26

> Plus more biotech news updates, brought to you by The Readout

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/01/23/biotech-news-insurers-blame-drugmakers-hospitals-for-prices/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Health insurance execs shift blame for costly, confusing health care system

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-22 20:11

> Health insurance execs blame the high cost of health care on hospitals, doctors, and prescription drugs.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/01/22/health-insurance-execs-blame-high-costs-hospitals-doctors-pharma/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: France rebuffs Trump over drug-pricing boast

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-22 15:58

> And more biotech news from The Readout newsletter

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/01/22/biotech-news-2/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Pharmalittle: Weâ€™re reading about Europeâ€™s pharma supply chain, stopping GLP-1 drugs, and more

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-22 14:26

> Many patients using GLP-1 drugs like Wegovy may not regain lost weight quickly when they stop treatment, an analysis of real-world data shows

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/01/22/europe-insulin-novo-weight-cvs-pharmacies/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Anthony Letai says NCI is more stable than perceived and is heading for a big year

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-22 09:30

> Anthony Letai says the National Cancer Institute is more stable than perceived and is heading for a big year.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/01/22/national-cancer-institute-director-anthony-letai-q-and-a/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Novo strikes deal for diabetes cell therapies

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-21 14:53

> And other biotech news, brought to you by The Readout newsletter

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/01/21/biotech-news-novo-nordisk-acquires-aspect-biosystems/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ Congress revives health care deal with PBM reforms

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-20 15:31

> This is the web edition of D.C. Diagnosis, STAT's twice-weekly newsletter about the politics and policy of health and medicine.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/01/20/congress-revives-health-care-deal-pbm-reforms-dc-diagnosis-newsletter/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Benefit from Modernaâ€™s skin cancer immunotherapy endures

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-20 14:47

> And other biotech news brought to you by the Readout Newsletter

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/01/20/biotech-news-moderna-merck-skin-cancer-mrna/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Pharmalittle: Weâ€™re reading about drug prices in Europe, a cancer vaccine, and much more

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-20 14:20

> U.S. pharmaceutical companies are stepping up their campaign for higher drug prices in Europe, in some cases threatening to withhold new medicines

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/01/20/pharma-prices-china-gsk-aids-cancer-vaccine-europe/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Florida proposes cutting eligibility for an AIDS drug program, causing panic

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-20 09:30

> In a surprise move, Florida officials have proposed drastically reducing eligibility for the state AIDS drug assistance program.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/pharmalot/2026/01/20/florida-hiv-aids-gilead-health-insurance/?utm_campaign=rss)

---

### ğŸ‡ºğŸ‡¸ STAT+: Congress revives bipartisan health care proposal, including drug middlemen provisions

- **æ¥æº**: STAT News - Pharma
- **æ—¶é—´**: 2026-01-20 01:03

> Elements of a health care deal that was blown up by Elon Musk are getting a fresh look in Congress.

ğŸ”— [é˜…è¯»åŸæ–‡](https://www.statnews.com/2026/01/19/bipartisan-health-care-package-pharmacy-benefit-manager/?utm_campaign=rss)

---

## ç›‘ç®¡å®¡æ‰¹ | Regulatory

### ğŸ‡ºğŸ‡¸ Drugs@FDA Data Files

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-23 13:58
- **é‡è¦æ€§**: â­â­

> Drugs@FDA Downloadable Data File in ZIP format, Data Definitions, and Entity Relationship Diagram (ERD)

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/drug-approvals-and-databases/drugsfda-data-files)

---

### ğŸ‡ºğŸ‡¸ Questions and Answers: Integration of FDA Facility Evaluation and Inspection Program for Human Drugs: A Concept of Operations

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-22 17:27
- **é‡è¦æ€§**: â­â­

> Questions and Answers: Integration of FDA Facility Evaluation and Inspection Program for Human Drugs: A Concept of Operations

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/pharmaceutical-quality-resources/questions-and-answers-integration-fda-facility-evaluation-and-inspection-program-human-drugs-concept)

---

### ğŸ‡ºğŸ‡¸ Registered Outsourcing Facilities

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-22 14:32
- **é‡è¦æ€§**: â­â­

> Discover FDA's comprehensive list of registered outsourcing facilities engaged in human drug compounding. Get the latest updates, compliance guidelines, and resources to ensure safe, high-quality compounded medications. Explore regulations and stay informed with verified facility details.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/human-drug-compounding/registered-outsourcing-facilities)

---

### ğŸ‡ºğŸ‡¸ Bodynplant - Online Advisory Letter

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-22 14:21
- **é‡è¦æ€§**: â­â­

> FDA Online advisory letter issued to Bodynplant/bodynplant.com for serious disease claims, including: cancer, diabetes, and HIV-AIDS

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/bodynplant-online-advisory-letter)

---

### ğŸ‡ºğŸ‡¸ What's New Related to Drugs

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-21 22:55
- **é‡è¦æ€§**: â­â­

> Want to know what's new on drugs from FDA? This page provides quick links to the latest on a variety of topics including: drug approvals, safety warnings, drug shortages, etc.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/news-events-human-drugs/whats-new-related-drugs)

---

### ğŸ‡ºğŸ‡¸ Drug Trials Snapshots

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-21 22:45
- **é‡è¦æ€§**: â­â­

> Drug Trials Snapshots: breaking down the what, how and why. Drug Trials Snapshots is part of an overall FDA effort to make demographic data more available and transparent.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots)

---

### ğŸ‡ºğŸ‡¸ C3TI Compass (Knowledge Repository)

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-22 14:46
- **é‡è¦æ€§**: â­

> Centralized knowledge repository for clinical trial innovation

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/about-fda/cder-center-clinical-trial-innovation-c3ti/c3ti-compass-knowledge-repository)

---

### ğŸ‡ºğŸ‡¸ Bayesian Statistical Analysis (BSA) Demonstration Project

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-22 14:45
- **é‡è¦æ€§**: â­

> C3TI aims to increase experience in Bayesian statistical methods in simple trial settings across sponsors, CDER clinical reviewers, and CDER statisticians, including deepening an understanding of their applicability, opportunities, and challenges.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/about-fda/cder-center-clinical-trial-innovation-c3ti/bayesian-statistical-analysis-bsa-demonstration-project)

---

### ğŸ‡ºğŸ‡¸ Clinical Outcome Assessment (COA): Frequently Asked Questions

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-22 13:16
- **é‡è¦æ€§**: â­

> Clinical Outcome Assessments (COA) Frequently Asked Questions

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/about-fda/clinical-outcome-assessment-coa-frequently-asked-questions)

---

### ğŸ‡ºğŸ‡¸ Genetic Metabolic Diseases Advisory Committee (GeMDAC) Charter

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-23 21:18

> The Genetic Metabolic Diseases Advisory Committee (GeMDAC) advises the Commissioner of Food and Drugs or designee in discharging responsibilities as they relate to helping to ensure safe and effective drugs and biologic products for human use and as required.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/advisory-committees/genetic-metabolic-diseases-advisory-committee/genetic-metabolic-diseases-advisory-committee-gemdac-charter)

---

### ğŸ‡ºğŸ‡¸ Real-World Evidence

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-23 18:08

> Real-world data (RWD) and real-world evidence (RWE) played an increasing role in health care decisions. The 21st Century Cures Act, passed in 2016, placed additional focus on the use of these types of data to support regulatory decision making.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/science-research/science-and-research-special-topics/real-world-evidence)

---

### ğŸ‡ºğŸ‡¸ Generic Drug User Fee Amendments

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-23 18:02

> This page features news and information for industry and stakeholders about GDUFA, its fee structure, payment methods, and related information.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/industry/fda-user-fee-programs/generic-drug-user-fee-amendments)

---

### ğŸ‡ºğŸ‡¸ Office of New Drugs Custom Medical Queries (OCMQs)

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-23 17:08

> Office of New Drugs Custom Medical Queries (OCMQs) are standardized groupings of similar adverse event terms intended to assist with the identification of potential safety issues during review of adverse event data.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/development-resources/office-new-drugs-custom-medical-queries-ocmqs)

---

### ğŸ‡ºğŸ‡¸ Drug Shortages

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-23 16:48

> Drug Shortages Homepage

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/drug-safety-and-availability/drug-shortages)

---

### ğŸ‡ºğŸ‡¸ List of Drug Master Files (DMFs)

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-23 15:41

> The list is updated quarterly.&nbsp;Changes are made to the DMF activity status, DMF type, holder name, and subject.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/drug-master-files-dmfs/list-drug-master-files-dmfs)

---

### ğŸ‡ºğŸ‡¸ Novel Drug Approvals for 2025

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-23 15:35

> Innovative drugs often mean new treatment options for patients and advances in health care for the American public.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025)

---

### ğŸ‡ºğŸ‡¸ Generic Drug Facilities, Sites and Organization Lists

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-23 13:52

> Generic Drug Facilities, Sites and Organization Lists

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/industry/generic-drug-user-fee-amendments/generic-drug-facilities-sites-and-organization-lists)

---

### ğŸ‡ºğŸ‡¸ Products Claiming to "Cure" Cancer Are a Cruel Deception

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-22 14:03

> Many ads on social media and "healthy" websites claim their products can cure cancer. They cannot.

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/consumers/consumer-updates/products-claiming-cure-cancer-are-cruel-deception)

---

### ğŸ‡ºğŸ‡¸ Advisory Letters

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-22 13:44

> Advisory Letters

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/advisory-letters)

---

### ğŸ‡ºğŸ‡¸ Drug Trials Snapshots KYGEVVI

- **æ¥æº**: FDA News
- **æ—¶é—´**: 2026-01-21 22:43

> Drug Trials Snapshots KYGEVVI

ğŸ”— [é˜…è¯»åŸæ–‡](http://www.fda.gov/drugs/drug-approvals-and-databases/drug-trials-snapshots-kygevvi)

---

## å•†ä¸šåŠ¨æ€ | Business/M&A

### ğŸ‡ºğŸ‡¸ ErVimmune raises 17m euros in funding to develop cancer vaccine

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-22 14:10
- **é‡è¦æ€§**: â­â­

> The vaccine could be created as a ready-to-use product, rather than needing to be personalised

ğŸ”— [é˜…è¯»åŸæ–‡](https://pharmatimes.com/news/ervimmune-raises-17m-euros-in-funding-to-develop-cancer-vaccine/)

---

### ğŸ‡ºğŸ‡¸ Scottish Medicines Consortium becomes first in UK to adopt new precision gastric cancer treatment

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-19 14:34
- **é‡è¦æ€§**: â­â­

> Decision introduces zolbetuximab for eligible patients in NHS Scotland

ğŸ”— [é˜…è¯»åŸæ–‡](https://pharmatimes.com/news/scottish-medicines-consortium-becomes-first-in-uk-to-adopt-new-precision-gastric-cancer-treatment/)

---

### ğŸ‡ºğŸ‡¸ AAX Biotech and Vascurie announce new neuro-oncology collaboration

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-20 12:41
- **é‡è¦æ€§**: â­

> The collaboration will help to advance a pipeline of antibody candidates

ğŸ”— [é˜…è¯»åŸæ–‡](https://pharmatimes.com/news/aax-biotech-and-vascurie-announce-new-neuro-oncology-collaboration/)

---

### ğŸ‡ºğŸ‡¸ Nxera Pharma reports positive results from phase 3 insomnia trial in South Korea

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-19 14:42
- **é‡è¦æ€§**: â­

> Company prepares marketing submission after treatment shows strong efficacy

ğŸ”— [é˜…è¯»åŸæ–‡](https://pharmatimes.com/news/nxera-pharma-reports-positive-results-from-phase-3-insomnia-trial-in-south-korea/)

---

### ğŸ‡ºğŸ‡¸ Book your tickets and join the PM Society for the 40th PM Awards on 20 March 2026

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-22 12:36

> The PM Awards celebrate creativity in pharmaceutical marketing and healthcare communications

ğŸ”— [é˜…è¯»åŸæ–‡](https://pharmatimes.com/news/book-your-tickets-and-join-the-pm-society-for-the-40th-pm-awards-on-20-march-2026/)

---

### ğŸ‡ºğŸ‡¸ Sun Pharmaâ€™s Unloxcyt now available in US for advanced cutaneous squamous cell carcinoma

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-21 12:13

> More than 71% of patients treated with Unloxcyt achieved disease control

ğŸ”— [é˜…è¯»åŸæ–‡](https://pharmatimes.com/news/sun-pharmas-unloxcyt-now-available-in-us-for-advanced-cutaneous-squamous-cell-carcinoma/)

---

### ğŸ‡ºğŸ‡¸ Peter Llewellyn-Davies

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-21 12:02

> ARTCLINE appoints Peter Llewellyn-Davies as Chairman of its Supervisory Board

ğŸ”— [é˜…è¯»åŸæ–‡](https://pharmatimes.com/appointments/peter-llewellyn-davies/)

---

### ğŸ‡ºğŸ‡¸ Venner Shipley announces opening of new Bristol office

- **æ¥æº**: Pharma Times
- **æ—¶é—´**: 2026-01-20 12:42

> The firm already has a number of offices across the UK and Europe

ğŸ”— [é˜…è¯»åŸæ–‡](https://pharmatimes.com/news/venner-shipley-announces-opening-of-new-bristol-office/)

---


---

*Generated by Pharma Daily - åˆ¶è¯èµ„è®¯èšåˆç³»ç»Ÿ*

*2026-01-26 03:56:03*